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Abstract
Background: Uromodulin kidney disease (UKD) is an inherited kidney disease caused by a uromodulin (UMOD) genemutation.
The UMOD gene encodes the Tamm–Horsfall protein (THP), which is the most abundant protein in healthy human urine.
Because of its rarity, the incidence of UKD has not been fully elucidated. The purpose of the present study is to clarify the
frequency of UKD among patients who underwent renal biopsy.
Methods: Immunostaining for THP was performed for patients <50 years of age with renal insufﬁciency and hyperuricemia
without overt urinalysis abnormality from renal biopsy databases. Serum and urinary THP concentrations were evaluated in
available individuals.
Results: Fifteen patients were selected for immunostaining from a total of 3787 patients. In three independent patients,
abnormal THP accumulation in renal tubular cells was observed. A novel missense A247P UMODmutation was detected in two
of the three patients, including one having a typical family history of familial juvenile hyperuricemic nephropathy. Serum and
urinary THP concentrations of all available patientswith UMODA247Pmutationwere signiﬁcantly lower than those of controls.
Conclusions: In the present study, UKDwas detected in <1 in 1000 subjectswho underwent renal biopsies. However, in subjects
meeting all of the above criteria, abnormal THP accumulation was detected in 20% (3/15), suggesting that renal biopsy with
immunostaining for THP is a good tool for diagnosing UKD. Also, low serumTHP concentration detected in the present subjects
might be a good diagnostic marker or important in understanding the pathogenesis of UKD.
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Familial juvenile hyperuricemic nephropathy (FJHN) is character-
ized by urinary concentration defect, hyperuricemia, gout and
progressive renal failure. Affected patients usually reach end-
stage kidney disease (ESKD) between the fourth and seventh
decade [1]. Uromodulin (UMOD) gene mutations have been
found in FJHN, medullary cystic kidney disease type 2 (MCKD2)
and glomerulocystic kidney disease (GCKD). These diseases
share some clinical features and are called uromodulin kidney
disease (UKD) [2, 3]. Recently a new disease category, autosomal
dominant tubulointerstitial kidney disease (ADTKD), was pro-
posed for the purpose of avoiding confusion arising from the
use of multiple names for the same condition [4]. UKD is also
called ADTKD-UMOD accordingly. UMOD gene encodes the
Tamm–Horsfall protein (THP), which is the most abundant pro-
tein in human urine. Urinary THP is reported to protect against
urinary tract infection [5], prevent urolithiasis [6], ensure water
impermeability and create the countercurrent gradient [7].
Recently a number of genome-wide association studies have
revealed that particular variants of the UMOD gene are asso-
ciated with the risk of developing chronic kidney disease (CKD)
or hypertension [8, 9]. However, the exact function of THP and
themechanism by which mutated THP triggers UKD are still elu-
sive. Although >100 UKD families have been reported, the exact
epidemiology of this condition is still unclear [10]. Also, aware-
ness of this disease is not sufﬁcient among clinicians, meaning
that a considerable number of UKD patients have likely reached
end-stage kidney disease (ESKD)with only an ambiguous diagno-
sis of CKD, despite undergoing renal biopsy. The aim of the pre-
sent study is to elucidate the frequency of UKD among patients
who underwent renal biopsy.
Subjects and methods
Subjects
Clinical data of 3787 patients who underwent renal biopsy at the
Kanazawa University hospital and afﬁliated medical facilities
from 1992 to 2013 were analyzed. Immunostaining for THP was
performed in renal sections of patients whomet all of the follow-
ing criteria: (i) renal insufﬁciency [serum creatinine (sCr) > 1.0
mg/dL] at <50 years of age, (ii) hyperuricemia (serum uric acid
>7 mg/dL) or under treatment for hyperuricemia, (iii) no or only
very mild abnormalities in urinalysis and (iv) no other apparent
renal disease present clinically or histopathologically.
The DNA of patients who had an abnormal THP staining pat-
ternwere analyzed for sequence analysis of the UMOD gene after
written informed consent was obtained. Serum and urinary THP
concentrations were measured in individuals who were diag-
nosed with UKD and 135 individuals (62% men, mean age
64.4 ± 16.6 years, mean eGFR 66.4 ± 34.0 mL/min) with glomerulo-
nephritis, nephrosclerosis, interstitial nephritis, diabetes melli-
tus or controls without kidney disease.
Methods
Immunostaining
THPwas stained with anti-THP rabbit polyclonal antibody (Santa
Cruz Biotechnology, Dallas, TX, USA). Anti-PDI (protein disulﬁde
isomerase) mouse monoclonal antibody (Enzo Life Sciences,
Farmingdale, NY, USA) was used for endoplasmic reticulum
(ER) staining together with THP staining. Fluorescence-labeled
antibody Alexa Flour 488 donkey anti-mouse IgG and Alexa
Flour 594 donkey anti-rabbit IgG (Invitrogen, Carlsbad, CA, USA;
dilution 1:200) were used for detection with Biorevo BZ-9000
(KEYENCE, Osaka, Japan). Abnormal accumulation of THP was
positive when clusters of THP were seen in >90% of THP-positive
tubules and negativewhenmost THP showed a granular or linear
appearance.
Mutation analysis
Genetic DNAs were extracted from peripheral blood leukocytes.
AmpliTaq gold DNA polymerase (Applied Biosystems, Foster
City, CA, USA) and a universal touchdown thermal cycling pro-
gramwith GeneAtlas PC 320 (Astec, Fukuoka, Japan) were applied
as described [11]. For some GC-rich regions, LATaq (Takara Bio,
Otsu, Japan) was used as DNA polymerase for PCR as recom-
mended by the manufacturer. The speciﬁc ﬂanking primers for
the mutation analysis of UMOD were referred to Hart et al. [2].
After puriﬁcation using a BigDye X Terminator Puriﬁcation Kit
(Applied Biosystems), the ampliﬁed PCR products containing
exons were sequenced in both directions on an automatic ﬂuor-
escence sequencer (ABI Prism 310 DNA sequencer, Applied Bio-
systems) using a dye terminator thermal cycle sequencing kit
(Amersham Biosciences, Piscataway, NJ, USA).
Haplotype analysis
Linkage analysis to the UMOD genewas performedwith six poly-
morphic microsatellite markers: cen – D16S3046 – D16S773 –
D16S3217 – D16S749 – D16S3036 – D16S3041 – tel. Fluorescently
labeled PCR products were detected with an ABI Prism 310
genetic analyzer (Applied Biosystems) and were analyzed using
Genemapper software (Applied Biosystems).
Quantitative analysis of THP concentration by ELISA
Serum and urinary THP concentrations were measured with a
commercially available enzyme-linked immunosorbent assay
(ELISA) kit (BioVendor, Brno, Slovenia). Fresh urine and serum
sampleswere kept frozen after collection until themeasurement.
Urinary THP concentration was corrected according to the
urinary creatinine level. The results are expressed as mean ± SD
unless stated otherwise.
Potential differences of urinary and serum THP concentrations
between groupswere evaluated by non-parametricMann–Whitney
test. A P-value <0.05 was regarded as statistically signiﬁcant.
Correlations were tested using the Spearman’s test.
Results
Immunostaining
Fifteen of 3787 patients met all of the criteria and immunostain-
ing for THP was performed for them. Clinical characteristics of
the 15 patients are shown in Table 1. Since the presence or ab-
sence of a family history was not a required item on the renal bi-
opsy request form, ‘positive’ refers only to cases in which
comments regarding a positive family history were noted in the
free space of the form. Three of the 15 patients listed in Table 1
had abnormal THP staining in tubular cells of their renal kidney
sections (Figure 1). Their THP staining was collocalized with PDI,
which is an ER resident chaperone protein in double ﬂuorescent
immune staining (Figure 2). We could not ﬁnd abnormal THP
staining in 10 individuals between 50 and 60 years old who met
other criteria (data not shown).
Case 6 stopped visiting the hospital after she underwent renal
biopsy, and sincewewere unable to contact her or her family, her


















DNA could not be obtained. This meant that the UMOD sequen-
cing analysis could be performed in only cases 12 and 14. Hetero-
zygosity for a novelmissensemutationwas identiﬁed in exon 3 in
the two patients. There was a base exchange (c. 739G>C) in pos-
ition 739, which led to replacement of the amino acid alanine
with proline in the protein in codon 247 (p.Ala247Pro). This
Table 1. Clinical characteristics of 15 patients with renal insufﬁciency and hyperuricemia without urinalysis abnormality at <50 years of age
Case number Year FH Age (years) Sex sCr (mg/dL) S-UA (mg/dL) U-prot U-ob Renal pathology
1 1992 − 44 M 1.3 7.3 ± ± Nephrosclerosis
2 1992 − 19 M 1.0 8.5 − ± ESKD
3 1993 − 28 M 3.1 T − − TIN, nephrosclerosis
4 1994 − 36 M 2.0 7.9 ± − TIN
5 1994 − 50 F 2.6 7.2 − − TIN, nephrosclerosis
6 1996 − 47 F 1.5 7.8 − − TIN
7 1996 − 35 M 2.5 13.2 − − TIN
8 1998 − 28 F 2.1 8.4 – ± Nephrosclerosis
9 1999 − 26 M 1.0 7.7 – – Nephrosclerosis
10 2000 − 37 M 8.2 9.4 – – TIN
11 2004 − 49 M 1.5 T − − TIN, nephrosclerosis
12 2005 − 31 M 1.31 7.8 − − TIN
13 2005 − 48 M 1.26 8.5 − − TIN
14 2007 + 29 M 1.4 9 − − TIN, nephrosclerosis
15 2009 − 34 M 2.64 12.8 − − Nephrosclerosis
FH, family history of kidney disease; sCr, serum creatinine; S-UA, ; U-prot, ; U-ob; M, male; F, female; T, treated for hyperuricemia; TIN, tubulointerstitial nephritis;
ESKD, end-stage kidney disease.
Fig. 1. THP immunostaining images of 15 patients (1–15) with renal insufﬁciency and hyperuricemia but abnormal urinalysis at <50 years of age and a control (C). In the
control kidney, THP shows diffuse cytoplasmic staining andmost abundant signals in the apical membrane. In the kidneys of cases 6, 12 and 14, massive clusters of THP
accumulate intracellularly.


















mutation did not exist in theDNAof 50 normal persons or the un-
affected father of case 14. Affected available family members of
case 14 (II-2, II-5) had the same A247P mutation (Figure 3).
Haplotype analysis
Haplotype analysis with six polymorphic microsatellites was
performed in all available individuals in family 14 and case 12. Al-
though in case 12 their alleles could not clearly be assigned to one
haplotype because DNA from his family was not available, under
the assumption of a shared haplotype, the haplotype colored in
pink showed cosegregation with the phenotype (Figure 3).
Clinical data
Case 14 (proband, III-4 of family14)
At a medical checkup at the age of 22 years, sCr (1.4 mg/dL) and
uric acid (9.0 mg/dL) were noted. Renal biopsy was performed
and focal tubulointerstitial nephropathy was detected. No cysts
were detected in his kidneys on ultrasound. There was a small
stone in his left kidney. He is currently 32 years old and his sCr
is 2.41 mg/dL. His mother (II-2) experienced a gout attack at the
age of 40 years and started uric acid – lowering and antihyperten-
sive therapy at that time. At the age of 62 years her sCr level in-
creased to 2.5 mg/dL. Her sister (II-5) is currently 71 years old
with an sCr of 2.26 mg/dL. Their father (I-3) experienced gout
attacks from a young age and started hemodialysis (HD) therapy
at the age of 60 years. He died of ileus caused by dialysis-
related amyloidosis at the age of 73 years.
Case 12
Hyperuricemia was noted out when the patient was 26 years old.
At 30 years, he experienced a gout attack. Renal biopsy was per-
formed because of gradually worsening renal insufﬁciency at 31
years. An obvious family history of renal disease was absent. His
urinalysis was normal. His current age is 42 years and his sCr is
1.57 mg/dL.
Fig. 2. Immunohistochemical images of kidney samples from control (a–c) and cases 6 (d–f ), 12 (g–i) and 14 ( j–l). Kidney sections were stained simultaneously with THP
(a, d, g, j) and PDI (b, e, h, k) andmerged (c, f, i, l). Nuclei were stainedwith DAPI. In the control kidney, diffusely scattered ﬁne signals of THPwere shown in the cytoplasm.
In cases 6, 12 and 14, abundant accumulated THP signals strongly collocalize with PDI, indicating that THP abnormally accumulated in the ER.



















When shewas 47 years old, renal biopsy was performed for renal
insufﬁciency without any abnormalities on urinalysis. She had
no family history of kidney disease. Subsequent clinical informa-
tion is not available.
Serum and urinary THP concentrations
In individuals with various kidney diseases and controls, serum
and urinary THP concentrations were positively correlated with
eGFR (Supplementary Figure S1), as already reported [12, 13]. How-
ever, serum THP concentrations showed a stronger correlation
(r= 0.604)with eGFR thandidurinaryTHPconcentrations (r = 0.325).
Serum and urinary THP concentrations of affected patients
with an A247P UMODmutationwere comparedwith those of kid-
ney disease patients whose GFR showed similar values (Figure 4).
Urinary THP concentrations of patients with A247P UMODmuta-
tionswere signiﬁcantly lower than those of controlswith an eGFR
<44 mL/min (P = 0.003172).
Serum THP concentrations of A247P patients were signiﬁ-
cantly lower compared with controls with similar eGFR values
(P < 0.00001) but were not different from serum THP concentra-
tions of ESRD patients on HD (P = 0.1127).
Discussion
UKD is a rare inherited disease. Based on renal replacement
therapy (RRT) patient surveys, the calculated prevalence of
UKD is reported to be 1.67 cases per million population and
0.73 per 1000 RRT patients in Austria [14] and 1.52 patients per
million population and 0.58 per 1000 RRT patients in the
Czech Republic [7].
It is suggested that hereditary tubulointerstitial nephritismay
be underrecognized, as the hallmarks of this disease are also
common in patients with other CKD, and a family history may
be absent or unknown [15].
In the present study, two UKD patients were detected among
3787 patients who underwent renal biopsies. Interestingly, both
independent patients had the same A247P UMOD mutation.
Haplotype analysis of their DNA indicated that they have a high
possibility of sharing one ancestor.
Although the DNA of case 6 was not available, this patient is
also assumed to have UKD, because of the abnormal THP accu-
mulation in her kidney samples. Case 14 had been surmised to
have FJHN before renal biopsy, because of his family history of
kidney disease. Meanwhile, case 12 had no such obvious history.
This suggests a wide spectrum of phenotypes among patients
with the same A247P UMOD mutation.
The C744G UMOD mutation in which the 248th cysteine is
substituted by tryptophan (Cys248Trp) is frequently found in Eur-
ope or Turkey, with this assumed to be due to a founder effect
[16]. This mutation causes both FJHN and MCKD. The A247P mu-
tation detected in the present study was the amino acid next to
this Cys248Trp mutation. They are located in D8C domains that
consist of eight conserved cysteine residues that are probably
involved in disulﬁde bond formation. Mutations of cysteine
Fig. 3. Pedigree, haplotype analysis andmutation analysis of family 14 and case 12. Affected individuals are represented by black symbols, the arrow indicates the proband,
deceased individuals are slashed and HD means individuals undergoing hemodialysis therapy. In the UMOD gene mutation analysis of all of the available affected
individuals (II-2, II-5 and III-4) in family 14 and case 12, the same A247P UMOD gene mutation (c.739G>C) was detected. Note that the sequence of II-6 (father of the
proband) showswild-type sequence. They also seem to share a cosegregated haplotype (colored in pink), indicating a high possibility that they share a common ancestor.


















residues in D8C domains lead to misfolding andmistransporting
of THP, resulting in abnormal deposition of THP in the ER. Muta-
tion of 247Ala is assumed to have the same effect.
THP is exclusively synthesized in the epithelial cells lining the
thick ascending limb (TAL) of Henle’s loop and predominantly
targeted apically and secreted in urine. However, a little THP is
basolaterally targeted and released in the serum [17]. Although
the signiﬁcance and function of serum THP are not fully under-
stood, its concentration is reported to be 45–490 ng/mL in the
serum of healthy individuals and associated with kidney func-
tion [13]. Serum THP concentrations in UKD patients are still elu-
sive. Very high or very low serum THP concentrations were
reported in UKD patients with C77Y and C126R UMODmutations
[18]. Prajczer et al. [19] reported that serum THP concentrations in
UKD patients did not differ as compared with healthy controls
and showed a very broad range.
THP extracted from the urine in UKD patients has been re-
ported to be signiﬁcantly low in various reports based on the re-
sults of impaired THP trafﬁcking in TAL cells [20]. In the present
report, both the serumandurinary THP concentrations of patients
with an A247P UMODmutationwere statistically lower than those
of controls with similar eGFRs. However, the decrease of serum
THP concentrations was more prominent than that of urinary
THP concentrations. In the future this investigation should be ex-
panded to also include individuals with other UMODmutations.
A renal ischemia-reperfusion experiment in UMOD knockout
mice showed signiﬁcantly worse results than in wild-type ani-
mals [21]. In another animal experiment, THP was reported to
shift from the apical toward the basolateral membrane by
induced ischemic injury [22]. These results indicate that serum
THP may exert a renoprotective effect against various types of
injury.
In conclusion, the number of UKD patients is very small (<1 in
1000 patients) in renal biopsy based populations. However, 2 de-
ﬁnitive and 1 probable UKD patients were detected among 15 pa-
tients with renal insufﬁciency, and hyperuricemia without
urinalysis abnormality at <50 years of age. All available A247P
UMOD patients showed signiﬁcantly low serum THP
Fig. 4. Serum and urinary THP concentrations of affected patients with an A247P UMODmutation. Serum THP concentrations were measured in 42 samples from 35 CKD
patients with eGFR <44 mL/min, 10 samples from 4 UKD patients with an A247P mutation (II-2, II-5, III-4 of family 14 and case 12) and 4 chronic HD patients. (A) Plots
showing eGFR of CKD with eGFR < 44 mL/min (27.74 ± 10.60 mL/min) and UKD (25.25 ± 7.86 mL/min) that is not statistically different and (B) serum THP concentrations
of CKD eGFR < 44 mL/min, UKD and HD patients. All of the available patients with an A247P mutation showed signiﬁcantly lower serum THP concentrations compared
with individuals with similar eGFR but not different from serumTHP concentrations of HD patients. (C) Urinary THP concentrationsweremeasured in 94 samples from 90
individuals with eGFR > 44 mL/min (eGFR 73.74 ± 19.45 mL/min), 17 samples from 16 CKD patients with eGFR < 44 mL/min (eGFR 28.05 ± 12.26 mL/min) and 13 samples
from 4 UKD patients with an A247P mutation (eGFR 25.86 ± 8.78 mL/min). The eGFR of the UKD group and CKD eGFR < 44 mL/min group are not statistically different.
(D) Plots showing urinary THP concentrations of CKD eGFR > 44 mL/min (10.74 ± 10.51 mg/g Cr), CKD eGFR < 44 mL/min (4.25 ± 4.01 mg/g Cr) and UKD
(1.5091 ± 0.6826 mg/g Cr). Urinary THP concentrations of patients with A247P UMOD mutations were signiﬁcantly lower compared with both groups. However, the
P-value was less signiﬁcant than that of serum THP concentrations (P = 0.003172 versus P < 0.00001).


















concentrations,whichmay be an important and speciﬁcﬁnding in
UKD. Serum THP might be a better marker for UKD than urinary
THPand alsomay be a good target forUKD treatment in the future.
Supplementary data
Supplementary data are available online at http://ckj.oxford
journals.org.
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